News

A pre-NDA meeting with the FDA discussed planned patient follow-up for patients with ROS1+ advanced non-small cell lung cancer in cohorts of the ongoing TRIDENT-1 study of repotrectinib.

Debra A. Patt, MD, PhD, MBA, discussed the use of digital health systems, particularly at Texas Oncology locations, and how it can help patients and providers strengthen their relationships.

Shana Wingo, MD, discusses the key goals of the partnership between community oncology practices and American Oncology Network.

: On the heels of positive findings from the phase 1/1b AURELIO-03, 1 patient with an advanced/refractory solid tumor has been dosed with SOT101 and pembrolizumab in the follow-up study, AURELIO-04.

Erika P. Hamilton, MD, discusses the evolution of fam-trastuzumab deruxtecan-nxki through its examination in various trials.

A refreshed platform serves as a critical foundation for the future of Florida Cancer Specialists.

Following positive phase 1/2 results of DS-7300 use in patients with extensive-stage small cell lung cancer, a phase 2 study has dosed its first patient with the experimental agent.

The experimental combination of tremelimumab, durvalumab, and stereotactic body radiotherapy lack overall surival benefit in anaplastic thryoid cancer, phase 1 findings show.

Alexander Drilon, MD, discusses the differences in how TRK fusions manifest in older patients vs younger patients.

Long-term follow-up in the COLUMBUS study shows continued survival improvement with encorafenib plus binimetinib and impressive disease control in patients with BRAF V600-mutant melanoma.

Treatment with ITI-3000 has begun in a first-in-human, phase 1 study of patients with Merkel cell carcinoma.

The FDA has accepted an application for the approval of fam-trastuzumab deruxtecan-nxki for the treatment of select adult patients with unresectable or metastatic HER2-low breast cancer.

Focused cancer centers increased hemithyroidectomy 2 years prior to the release of the newest American Thyroid Association guidelines. However, only community cancer program hospitals began to increase hemithyroidectomy utilization following release of guidelines.

In an interview with Targeted Oncology, Vignesh Packiam, MD, discussed the research of gemcitabine plus cabazitaxel and pembrolizumab in patients with non-muscle invasive urothelial carcinoma who are unresponsive to docetaxel.

Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.

The phase 3 CALGB 9343 study significantly changed prescription patterns for patients with metastatic colorectal cancer, according to a presentation at the International Society for Pharmacoeconomics and Outcomes Research 2022.

Data revealed that a longer time to treatment discontinuation seen with asciminib favored its relative tolerability, correlating with the better-observed safety profile, according to data presented at the International Society for Pharmacoeconomics and Outcomes Research 2022

Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

President Biden announced his intent to appoint Mitchel Berger, MD, Carol L. Brown, MD, and Elizabeth M. Jaffe, MD, to the President’s Cancer Panel to help aid in the Biden-Harris administration's renewed Cancer Moonshot Program.

In an interview with Targeted Oncology, Gerald Falchook, MD, discusses the efficacy and safety of cobolimab with or without nivolumab and dostarlimab, as evaluated in the phase 1 AMBER trial.

In COSMIC-312, reduction in the risk of disease progression or death was achieved with the combination of cabozantinib Plus atezolizumab compatient with sorafenib in patient with hepatocellular carcinoma.

The developer of OP-1250 anticipates working closely with the FDA to expedite the development of the drug for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer.

The phase 2 LOTIS-9 study of loncastuximab tesirine-lpyl combined with rituximab has been initiated with the dosing of the first patient with previously untreated diffuse large B-cell lymphoma.

Following positive phase 1 study results for eltanexor monotherapy in patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndrome, the FDA has granted the drug fast track status.

Valencia Thomas, MD, MHCM, MD Anderson Cancer Center, discusses the future for managing care in patients with non-melanoma skin cancers.

The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.

Patients with unresected locally advanced head and neck squamous cell carcinoma did not show a significant improvement in event-free survival when treated with pembrolizumab and concurrent chemoradiation followed by pembrolizumab maintenance in the phase 3 KEYNOTE-412 study.

The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

The FDA accepted review for the premarket approval supplement application for the Pan-cancer oncoReveal™ CDx.

The phase 2 THIO-101 clinical trial evaluating THIO in combination with cemiplimab in patients with advanced non—small cell lung cancer has dosed its first patient.